Vanguard Group
INTS icon

Vanguard Group’s Intensity Therapeutics INTS Stock Holding History

Vanguard Group’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$266K Buy
25,963
+15,726
+154% +$159K ﹤0.01% 4060
2025
Q3 		$62.2K Buy
10,237
+8,614
+531% +$61.6K ﹤0.01% 4274
2025
Q2 		$12.5K Sell
1,623
-7,603
-82% -$156K ﹤0.01% 4259
2025
Q1 		$454K Buy
9,226
+871
+10% +$48.4K ﹤0.01% 3910
2024
Q4 		$370K Hold
8,355
– – ﹤0.01% 4011
2024
Q3 		$798K Buy
8,355
+156
+2% +$17.3K ﹤0.01% 3837
2024
Q2 		$1M Buy
8,199
+1,112
+16% +$126K ﹤0.01% 3788
2024
Q1 		$921K Buy
7,087
+3,764
+113% +$451K ﹤0.01% 3844
2023
Q4 		$712K Buy
+3,323
New +$350K ﹤0.01% 3927

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
LA
Legacy Advisors Plymouth Meeting, Pennsylvania $1.07B AUM 26.49% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
SFGP
Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.32B AUM 23.07% 1-Year Est. Return

Vanguard Group's INTS Position: Q4 2025 in Review

Vanguard Group increased its Intensity Therapeutics (INTS) stake by 154% in Q4 2025, buying an estimated $159K and bringing the position to 25,963 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #4060.

Vanguard Group first reported a position in INTS in Q4 2023 and has held it in 9 quarters since. The position peaked at $1M in Q2 2024. 35 funds tracked by Wall St. Rank hold INTS as of Q4 2025.

  • Vanguard Group held 25,963 shares of Intensity Therapeutics worth $266K as of Q4 2025.
  • Vanguard Group bought 15,726 Intensity Therapeutics shares in Q4 2025, an estimated $159K.
  • Intensity Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4060 holding.
  • Vanguard Group first reported a position in Intensity Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Vanguard Group's Intensity Therapeutics position peaked at $1M in Q2 2024.
  • 35 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.